This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Radiofrequency ablation (RFA) is an important therapeutic modality for atrialfibrillation (AF), widely utilized in clinical practice due to its safety and significant efficacy. A 71-year-old male admitted to the emergency department on July 19, 2024, with acute loss of consciousness and convulsions.
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrialfibrillationablation, Musat et al. ERAT is often attributed to transient inflammation induced by tissue damage during ablation and short-term imbalances in autonomic innervation.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S. Circulation.
BackgroundAtrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide, posing significant health burdens. Pulsed field ablation (PFA) is an emerging non-thermal technique that is gaining traction due to the ability to selectively target myocardial cells and minimize damage to surrounding tissues.
milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024.
Previous studies evaluated its value in predicting atrialfibrillation (AF) occurrence. However, its predictive efficacy for AF recurrence remains controversial.MethodsWe searched PubMed and Google databases for studies before January 2024 evaluating the association between QTc interval and AF incidence.
Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. By guiding ablation therapy, [EGF mapping] can enable clinicians to provide personalized, highly targeted treatment."
milla1cf Fri, 02/02/2024 - 17:02 February 2, 2024 — Biosense Webster, Inc. , Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillationAblation," the study was presented as a late-breaker at the 29th Annual International AF Symposium.
Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. intermittent) atrialfibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific.
milla1cf Mon, 01/29/2024 - 11:00 January 29, 2024 — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San Antonio.
PFA on Display As you walked into the expo hall, it was hard to miss the large space-age light displays of the Farapulse Pulsed Field Ablation system from Boston Scientific and the PulseSelect PFA system from Medtronic. Pulsed field ablation (PFA) is all the rage in electrophysiology. So, again, innovation is great.
We appreciate the immense effort undertaken by the writing committee to produce the outstanding 2024 Consensus Statement on Catheter and Surgical Ablation of AtrialFibrillation (AF)(1). A notable omission exists in section 7.4:
milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrialfibrillation (AFib).
The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrialfibrillation.
Atrialfibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrialfibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. 2024, May 15).
ISC 2024 Late-breaking Science Finding from ZODIAC Study: Position of Head Before Surgery May Improve Stroke Patient’s Neurological Function 3. ISC 2024 News: Late-Breaking Science Findings from EMBOLISE Clinical Trial Reveals Blocking Artery Supplying the Brain Covering After Subdural Hematoma Reduced Repeat Surgery 4.
A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrialfibrillation (AF) and results in clinically important improvements in symptoms and quality of life compared with a sham (placebo) procedure, according to late breaking research presented Sept.
This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrialfibrillationablation shows a 66.7% identification rate of PLSVC-related triggers and an 85% success rate in acute isolation or targeted ablation. However, a 46.7% Results The cohort's mean age was 51.917.9 years, 31.2%
Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for AtrialFibrillation Treatment 8. Weight Loss Drug Linked with Reduced Need for Diuretics in Heart Failure Patients 7. Tenax Therapeutics Announces New U.S.
FDA approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrialfibrillation and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation System.
Circulation, Volume 150, Issue Suppl_1 , Page A4141066-A4141066, November 12, 2024. Background:Clinical studies on atrialfibrillation (AF) recurrence after catheter ablation in patients diagnosed with patent foramen ovale (PFO) and paroxysmal AF (PAF) are scarce.
Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrialfibrillation (AFib) ablation resulted in significantly less bleeding compared with oral anticoagulation, based on findings from the OPTION trial presented at AHA 2024 and simultaneously published in NEJM.
Pulsed Field Ablation is a relatively new modality for treatment of atrialfibrillation. In conventional ablation for atrialfibrillation, either heating of tissue is produced by radiofrequency application or freezing of tissues by cryoablation. That was a new analysis of the ADVENT trial [2]. N Engl J Med.
mtaschetta-millane Wed, 07/17/2024 - 11:06 July 17, 2024 — BioCardia, Inc. , This additional patent protection for BioCardia’s current and future products in this important existing market enhances shareholder value.
a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrialfibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
ABSTRACT Atrialfibrillation (AF) is the most common cause of arrhythmia-induced cardiomyopathy. Effective management strategies include medical therapy for rate and rhythm control, catheter ablation (CA), and goal-directed medical therapy. Our search yielded nine eligible studies with 16857 patients.
Pulsed field ablation (PFA) was shown to be effective in treating patients with paroxysmal atrialfibrillation (AFib), with more patients free from atrial arrhythmias (AA) when compared with patients treated with thermal ablation, according to results from a secondary analysis of the ADVENT trial.
Circulation, Volume 150, Issue Suppl_1 , Page A4139988-A4139988, November 12, 2024. Background:Ablation is an increasingly preferred treatment for patients with atrialfibrillation (AF), yet the optimal catheter configuration to record electrical activity (electrograms) is undefined.
Publication date: Available online 1 May 2024 Source: The American Journal of Cardiology Author(s): Raghav Chandra, Jason Guo, Jewon Sohn, Michael E. Jessen, Christopher A.
Circulation, Volume 150, Issue Suppl_1 , Page A4140664-A4140664, November 12, 2024. While studies have linked this genetic mutation to severe cardiac hypertrophy, a connection to persistent atrialfibrillation (AF) is unestablished. He was loaded with amiodarone. Monitoring on his apple watch showed a high burden of AF.
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
Atrioventricular nodal (AVN) ablation with permanent pacemaker implantation – ‘pace and ablate’ – may be considered for patients with symptomatic atrialfibrillation (AF) for whom rhythm control has been unsuccessful. Conduction-system pacing mitigates PICM, so we expect a greater uptake of AVN ablation going forward.
This study investigated the effect of EAT on the risk of SCI after atrialfibrillation catheter ablation (AFCA). We consecutively enrolled patients who underwent AFCA from October 2019 to February 2024. However, the relationship between EAT and silent cerebral infarcts (SCI) is unclear.
The most common arrhythmia, atrialfibrillation , will affect approximately 12.1 UC San Diego Health implanted the pacemaker system in the first patient in February 2024. “To Holding the device and pictured above is Ulrika Birgersdotter-Green, MD, cardiologist and director of pacemaker and ICD services at UC San Diego Health.
Circulation, Volume 150, Issue Suppl_1 , Page A4137989-A4137989, November 12, 2024. Background:A bimodal P wave in lead II reflects left atrial remodeling and is described as a notched P wave. A notched P wave is also known to predict atrialfibrillation (AF) after catheter ablation.
Nature Reviews Cardiology, Published online: 25 April 2024; doi:10.1038/s41569-024-01036-8 Treatment for periodontal disease might reduce the recurrence of atrialfibrillation (AF) in patients undergoing ablation, suggesting that periodontitis is a modifiable risk factor for AF.
Performing additional catheter ablations targeting diseased myocardium along with the standard approach of pulmonary vein isolation (PVI) to treat persistent atrialfibrillation (AFib) did not reduce the recurrence of AFib at one year, based on findings from the SUPPRESS-AF trial presented at ESC Congress 2024 in London.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content